Inês Martins, PhD, managing science editor —

Inês holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, Inês won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science.

Articles by Inês Martins

FDA approves tofersen, now Qalsody, as treatment for SOD1-ALS

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Biogen’s tofersen, now named Qalsody, for the treatment of amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene. The decision, which marks the first conditional approval for ALS in the country, comes about eight…

Researchers Identify New Genetic Defect Linked to ALS

Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role in the proteasome, a mechanism used…